A First in Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-3102
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

G1T48, an Oral Selective Estrogen Receptor Degrader, and the CDK4/6 Inhibitor Lerociclib Inhibit Tumor Growth in Animal Models of Endocrine-Resistant Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2020English

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Estrogen Receptor, Progesterone Receptor, and HER2-neu Expression in First Primary Breast Cancers and Risk of Second Primary Contralateral Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effects of Leptin on Human Breast Cancer Cell Lines in Relationship to Estrogen Receptor and HER2 Status

International Journal of Oncology
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy